Loading
Latest filing published 18 Mar 2026 for Lexaria Bioscience Corp..
Not enough history yet: 1 closed purchase, at least 2 are needed.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Filings by Christopher Bunka span 2 companies, the busiest being Lexaria Bioscience Corp. and Lexaria Corp. The record holds 72 filings, for trades running from 4 January 2016 to 17 March 2026.
On the market, this insider has only ever bought: 61 purchases, €155k in total. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 7 share grants and 2 option exercises.
A typical purchase (the median) is worth €792. 1 out of 22 purchases came within 30 days of a purchase by at least one other insider of the same company. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.
The record was last updated on 18 March 2026 with a transaction in Lexaria Bioscience Corp. The latest purchase dates back some time: it was published 451 days ago, on 30 July 2025. The median gap between a trade and its publication by SEC (Form 4) is 1 day. The legal deadline for a Form 4 is two business days after the transaction. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 71 declarations